In vitro selection of RNA aptamers that inhibit the activity of type A botulinum neurotoxin

Biochemical and Biophysical Research Communications

Volumn 396, Issue 4, 2010, Pages 854-860

  Chang, Tzuu Wang ^a   Blank, Michael ^b   Janardhanan, Pavithra ^a   Singh, Bal Ram ^a   Mello, Charlene ^c   Blind, Michael ^d   Cai, Shuowei ^a  

^a UNIVERSITY OF MASSACHUSETTS DARTMOUTH   (United States)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c US Army Natick Soldier RD and E Center   (United States)

^d NascaCell Technologies AG   (Germany)

Author keywords

Antidote; Aptamer; Botulinum neurotoxin; Endopeptidase; RNA

Indexed keywords

APTAMER; BOTULINUM TOXIN A; PROTEINASE; RNA APTAMER; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; COMBINATORIAL CHEMISTRY; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME KINETICS; FLACCID PARALYSIS; IC 50; IN VITRO STUDY; INHIBITION KINETICS; MOLECULAR MODEL; PRIORITY JOURNAL;

ANTIDOTES; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; BOTULINUM TOXIN TYPE A; SELEX APTAMER TECHNIQUE;

EID: 77953289484     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.05.006     Document Type: Article

References (26)

1. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., Fine A.D., Hauer J., Layton M., Lillibridge S., Osterholm M.T., O'Toole T., Parker G., Perl T.M., Russell P.K., Swerdlow D.L., and Tonat K. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285 (2001) 1059-1070
2. Wein L.M., and Liu Y. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc. Natl. Acad. Sci. USA 102 (2005) 9984-9989
3. Cai S., and Singh B.R. Strategies to design inhibitors of Clostridium botulinum neurotoxins. Infect. Disord. Drug Targets 7 (2007) 47-57
4. Rossetto O., Seveso M., Caccin P., Schiavo G., and Montecucco C. Tetanus and botulinum neurotoxins: turning bad guys into good by research. Toxicon 39 (2001) 27-41
5. Eubanks L.M., Hixon M.S., Jin W., Hong S., Clancy C.M., Tepp W.H., Baldwin M.R., Malizio C.J., Goodnough M.C., Barbieri J.T., Johnson E.A., Boger D.L., Dickerson T.J., and Janda K.D. An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc. Natl. Acad. Sci. USA 104 (2007) 2602-2607
6. Tuerk C., and Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249 (1990) 505-510
7. Nimjee S.M., Rusconi C.P., and Sullenger B.A. Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56 (2005) 555-583
8. Tang Z., Parekh P., Turner P., Moyer R.W., and Tan W. Generating aptamers for recognition of virus-infected cells. Clin. Chem. 55 (2009) 813-822
9. Li L., and Singh B.R. High-level expression, purification, and characterization of recombinant type A botulinum neurotoxin light chain. Protein Expr. Purif. 17 (1999) 339-344
10. Hunsicker A., Steber M., Mayer G., Meitert J., Klotzsche M., Blind M., Hillen W., Berens C., and Suess B. An RNA aptamer that induces transcription. Chem. Biol. 16 (2009) 173-180
11. Cai S., Lindo P., Park J.B., Vasa K., and Singh B.R. The identification and biochemical characterization of drug-like compounds that inhibit botulinum neurotoxin serotype A endopeptidase activity. Toxicon 55 (2010) 818-826
12. Ding F., Sharma S., Chalasani P., Demidov V.V., Broude N.E., and Dokholyan N.V. Ab initio RNA folding by discrete molecular dynamics: from structure prediction to folding mechanisms. RNA 14 (2008) 1164-1173
13. Chang D.T., Oyang Y.J., and Lin J.H. MEDock: a web server for efficient prediction of ligand binding sites based on a novel optimization algorithm. Nucleic Acids Res. 33 (2005) W233-W238
14. Lee P.H., Kuo K.L., Chu P.Y., Liu E.M., and Lin J.H. SLITHER: a web server for generating contiguous conformations of substrate molecules entering into deep active sites of proteins or migrating through channels in membrane transporters. Nucleic Acids Res. 37 (2009) W559-W564
15. Kumaran D., Rawat R., Ahmed S.A., and Swaminathan S. Substrate binding mode, its implication on drug design for botulinum neurotoxin A. PLoS Pathog. 4 (2008) e1000165
16. Burnett J.C., Schmidt J.J., Stafford R.G., Panchal R.G., Nguyen T.L., Hermone A.R., Vennerstrom J.L., McGrath C.F., Lane D.J., Sausville E.A., Zaharevitz D.W., Gussio R., and Bavari S. Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem. Biophys. Res. Commun. 310 (2003) 84-93
17. Lacy D.B., Tepp W., Cohen A.C., DasGupta B.R., and Stevens R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 5 (1998) 898-902
18. Dickerson T.J., and Janda K.D. The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication. ACS Chem. Biol. 1 (2006) 359-369
19. Burnett J.C., Opsenica D., Sriraghavan K., Panchal R.G., Ruthel G., Hermone A.R., Nguyen T.L., Kenny T.A., Lane D.J., McGrath C.F., Schmidt J.J., Vennerstrom J.L., Gussio R., Solaja B.A., and Bavari S. A refined pharmacophore identifies potent 4-amino-7-chloroquinoline-based inhibitors of the botulinum neurotoxin serotype A metalloprotease. J. Med. Chem. 50 (2007) 2127-2136
20. Burnett J.C., Ruthel G., Stegmann C.M., Panchal R.G., Nguyen T.L., Hermone A.R., Stafford R.G., Lane D.J., Kenny T.A., McGrath C.F., Wipf P., Stahl A.M., Schmidt J.J., Gussio R., Brunger A.T., and Bavari S. Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J. Biol. Chem. 282 (2007) 5004-5014
21. Burnett J.C., Schmidt J.J., McGrath C.F., Nguyen T.L., Hermone A.R., Panchal R.G., Vennerstrom J.L., Kodukula K., Zaharevitz D.W., Gussio R., and Bavari S. Conformational sampling of the botulinum neurotoxin serotype A light chain: implications for inhibitor binding. Bioorg. Med. Chem. 13 (2005) 333-341
22. Hermone A.R., Burnett J.C., Nuss J.E., Tressler L.E., Nguyen T.L., Solaja B.A., Vennerstrom J.L., Schmidt J.J., Wipf P., Bavari S., and Gussio R. Three-dimensional database mining identifies a unique chemotype that unites structurally diverse botulinum neurotoxin serotype A inhibitors in a three-zone pharmacophore. ChemMedChem 3 (2008) 1905-1912
23. Fan M., McBurnett S.R., Andrews C.J., Allman A.M., Bruno J.G., and Kiel J.L. Aptamer selection express: a novel method for rapid single-step selection and sensing of aptamers. J. Biomol. Tech. 19 (2008) 311-319
24. Lou X., Qian J., Xiao Y., Viel L., Gerdon A.E., Lagally E.T., Atzberger P., Tarasow T.M., Heeger A.J., and Soh H.T. Micromagnetic selection of aptamers in microfluidic channels. Proc. Natl. Acad. Sci. USA 106 (2009) 2989-2994
25. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31 (2003) 3406-3415
26. Breidenbach M.A., and Brunger A.T. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432 (2004) 925-929